Combining CTLA-4 Blockade and 4-1BB Activation to Enhance Tumor Rejection
Author Information
Author(s): Curran Michael A., Kim Myoungjoo, Montalvo Welby, Al-Shamkhani Aymen, Allison James P.
Primary Institution: Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan-Kettering Cancer Center
Hypothesis
Can combining CTLA-4 blockade with 4-1BB activation improve the rejection of poorly immunogenic tumors like B16 melanoma?
Conclusion
The combination of CTLA-4 blockade and 4-1BB activation significantly enhances the rejection of B16 melanoma tumors.
Supporting Evidence
- Combining αCTLA-4 and α4-1BB antibodies led to a 57% tumor rejection rate in treated mice.
- 4-1BB activation increased CD8+ T-cell infiltration into tumors.
- CTLA-4 blockade enhanced CD4+ effector T-cell proliferation.
- Combination therapy resulted in higher ratios of effector T-cells to regulatory T-cells in tumors.
Takeaway
This study found that using two different treatments together can help the body fight off a type of skin cancer better than using just one treatment.
Methodology
Mice were treated with a combination of αCTLA-4 and α4-1BB antibodies along with a Flt3-ligand based vaccine to assess tumor rejection.
Potential Biases
Potential bias due to the use of a specific mouse model and the controlled experimental conditions.
Limitations
The study primarily focused on a single tumor model and may not generalize to all types of tumors.
Participant Demographics
C57BL/6 mice, 4-6 weeks old, male.
Statistical Information
P-Value
p=0.0002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website